rjd970
Well-Known Member
- Joined
- Sep 19, 2007
- Messages
- 23,372
- Likes
- 22,175
Anybody see this?
http://www.nytimes.com/2015/09/21/b...se-in-a-drugs-price-raises-protests.html?_r=0
Also, this Shkreli character seems rather shady...
What say you? Good business or unethical capitalism?
http://www.nytimes.com/2015/09/21/b...se-in-a-drugs-price-raises-protests.html?_r=0
Specialists in infectious disease are protesting a gigantic overnight increase in the price of a 62-year-old drug that is the standard of care for treating a life-threatening parasitic infection.
The drug, called Daraprim, was acquired in August by Turing Pharmaceuticals, a start-up run by a former hedge fund manager. Turing immediately raised the price to $750 a tablet from $13.50, bringing the annual cost of treatment for some patients to hundreds of thousands of dollars.
Also, this Shkreli character seems rather shady...
This is not the first time the 32-year-old Mr. Shkreli, who has a reputation for both brilliance and brashness, has been the center of controversy. He started MSMB Capital, a hedge fund company, in his 20s and drew attention for urging the Food and Drug Administration not to approve certain drugs made by companies whose stock he was shorting.
In 2011, Mr. Shkreli started Retrophin, which also acquired old neglected drugs and sharply raised their prices. Retrophins board fired Mr. Shkreli a year ago. Last month, it filed a complaint in Federal District Court in Manhattan, accusing him of using Retrophin as a personal piggy bank to pay back angry investors in his hedge fund.
What say you? Good business or unethical capitalism?